Goldman Sachs Asset Management led a $150m Series B funding round in MOMA Therapeutics.

Goldman Sachs Asset Management, an investment manager, led a $150m Series B funding round in MOMA Therapeutics, an operator of a biotechnology platform, with participation from Section 32, Pavilion Capital, Invus, LifeSci Venture Partners, Third Rock Ventures, Nextech Invest, Cormorant Asset Management, Casdin Capital, Rock Springs Capital, Creacion Ventures and Alexandria Venture Investments. “This Series B gives us runway to move our precision medicines toward the clinic for patients in need. We welcome all new investors to our syndicate, including lead Goldman Sachs Asset Management, and are tremendously grateful to our existing investors for their steadfast support and commitment to MOMA’s vision and mission," Asit Parikh, MOMA CEO.